Goldman Sachs Upgrades Krystal Biotech to Buy, Raises Price Target to $124
Goldman Sachs analyst Madhu Kumar upgrades Krystal Biotech (NASDAQ:KRYS) from Neutral to Buy and raises the price target from $79 to $124.
Chardan Capital Reiterates Buy on Krystal Biotech, Maintains $133 Price Target
Chardan Capital analyst Geulah Livshits reiterates Krystal Biotech (NASDAQ:KRYS) with a Buy and maintains $133 price target.
Have A Look At William Blair’s Top Biotech Picks For 2023
William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period.
New England Journal Of Medicine Publishes Phase 3 Data On B-VEC In Patients With Dystrophic Epidermolysis Bullosa
Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that data from the
Recap: Krystal Biotech Q3 Earnings
Krystal Biotech (NASDAQ:KRYS) reported its Q3 earnings results on Monday, November 7, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ:KRYS) Biologics License Application (BLA)…
FDA Accepts Krystal Biotech’s Filing For Genetic Skin Disorder Candidate Under Priority Review
The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ: KRYS) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with dystrophic epidermolysis bullosa (DEB).
FDA Accepts Krystal Biotech’s Biologics License Application For Dystrophic Epidermolysis Bullosa
FDA granted Priority Review designation
PDUFA target action date is February 17, 2023
FDA stated that it is not currently planning to hold an advisory committee meeting
Recap Of Monday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ:ELDN) Investigational New Drug (IND) application…